This trial is evaluating the combination of 177Lu-girentuximab with nivolumab and cabozantinib to enhance the complete response rate in advanced clear-cell renal cell carcinoma (ccRCC). The aim is to activate cGAS-STING-induced antitumor immunity via targeted radioimmunotherapy damage to DNA. If successful, this approach could establish a novel paradigm that combines radiopharmaceuticals with immunotherapy and targeted therapy in ccRCC.
European urology focus. 2025 Apr 26 [Epub ahead of print]
Elshad Hasanov, Lesley Flynt, Rebecca Slack Tidwell, Hyunsoo Hwang, Roserika Brooks, Lauren Michelle Wood, Travis Solley, Mashaal Syed, Aradhana M Venkatesan, Eric Jonasch
Division of Medical Oncology, Pelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH, USA., Department of Nuclear Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Department of Abdominal Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: .